Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

908 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Katakami N, Yokoyama T, Morita S, Okamoto T, Urata Y, Hattori Y, Iwamoto Y, Sato Y, Ikeda N, Takahashi T, Daga H, Oguri T, Fujisaka Y, Nishino K, Sugawara S, Kozuki T, Oki M, Yamamoto N, Nakagawa K. Katakami N, et al. Among authors: nishino k. Int J Clin Oncol. 2023 Jan;28(1):79-88. doi: 10.1007/s10147-022-02266-x. Epub 2022 Nov 21. Int J Clin Oncol. 2023. PMID: 36414827 Clinical Trial.
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I. Shiraishi Y, et al. Among authors: nishino k. JAMA Oncol. 2024 Mar 1;10(3):315-324. doi: 10.1001/jamaoncol.2023.5258. JAMA Oncol. 2024. PMID: 38127362 Free PMC article. Clinical Trial.
Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment.
Tanaka S, Tamiya M, Nishiuma S, Nakamura S, Nozaki K, Watanabe N, Itoh C, Kadokawa Y, Takeda K, Takahashi K, Miyazaki A, Kawamura T, Kunimasa K, Inoue T, Nishino K, Takagi M. Tanaka S, et al. Among authors: nishino k. Cancer Treat Res Commun. 2024;40:100836. doi: 10.1016/j.ctarc.2024.100836. Epub 2024 Jul 30. Cancer Treat Res Commun. 2024. PMID: 39098310 Free article.
Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell lung cancer patient with severe tumor-associated liver failure: A case report.
Kunimasa K, Miyazaki A, Tamiya M, Inoue T, Kawamura T, Tanaka T, Futamura S, Komuta K, Nagata S, Honma K, Ohkawa K, Nishino K. Kunimasa K, et al. Among authors: nishino k. Thorac Cancer. 2024 Dec;15(36):2570-2574. doi: 10.1111/1759-7714.15487. Epub 2024 Nov 11. Thorac Cancer. 2024. PMID: 39527462 Free PMC article.
908 results